| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jean-Charles Paterna, Andreas Leng, Elisabeth Weber, Joram Feldon, Hansruedi Büele. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Molecular therapy : the journal of the American Society of Gene Therapy. vol 15. issue 4. 2007-05-22. PMID:17299411. |
our results show that parkin and dj-1 inhibit dopamine neuron death and enhance amphetamine-induced dopaminergic function in a mouse model of idiopathic pd. |
2007-05-22 |
2023-08-12 |
mouse |
| Zhongling Zheng, R Alberto Travagl. Dopamine effects on identified rat vagal motoneurons. American journal of physiology. Gastrointestinal and liver physiology. vol 292. issue 4. 2007-05-17. PMID:17170022. |
our aims were to investigate whether a subpopulation of neurons in the a2 area was dopaminergic and, if so, to investigate the effects of dopamine (da) on the membrane of gastric-projecting vagal motoneurons. |
2007-05-17 |
2023-08-12 |
rat |
| E Ch Wolter. PD-related psychosis: pathophysiology with therapeutical strategies. Journal of neural transmission. Supplementum. issue 71. 2007-05-17. PMID:17447413. |
parkinson's disease (pd) is a chronic, neurodegenerative disease with degeneration of the central dopaminergic neurons in the substantia nigra, leading to a depletion of dopamine (da) in the striatum. |
2007-05-17 |
2023-08-12 |
Not clear |
| Mufida El-Ghundi, Brian F O'Dowd, Susan R Georg. Insights into the role of dopamine receptor systems in learning and memory. Reviews in the neurosciences. vol 18. issue 1. 2007-05-15. PMID:17405450. |
one of the most important advances in the field of dopamine research has been the generation of mutant mouse models permitting evaluation of the dopaminergic system using gene targeting technologies. |
2007-05-15 |
2023-08-12 |
mouse |
| Lucyna Antkiewicz-Michaluk, Jerzy Michaluk, Irena Romańska, Piotr Popik, Martyna Krawczyk, Irena Nalepa, Jerzy Vetulan. Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological reports : PR. vol 58. issue 6. 2007-05-11. PMID:17220541. |
as revealed by hplc, dopamine metabolism in the nucleus accumbens was slightly decreased after 14 days of treatment with imipramine, and co-administration of nicotine resulted in a significant and much more pronounced depression of dopamine metabolism in all investigated dopaminergic structures. |
2007-05-11 |
2023-08-12 |
rat |
| Ignacio Cruz-Muros, Domingo Afonso-Oramas, Pedro Abreu, Pedro Barroso-Chinea, Manuel Rodríguez, M Carmen González, Tomás González Hernánde. Aging of the rat mesostriatal system: differences between the nigrostriatal and the mesolimbic compartments. Experimental neurology. vol 204. issue 1. 2007-05-10. PMID:17112516. |
here we used biochemical, molecular and morphological techniques directed at detecting flaws in the dopamine synthesis route and signs of dopaminergic degeneration in the rat mesostriatal system during normal aging. |
2007-05-10 |
2023-08-12 |
rat |
| Michael J Jackson, Lance A Smith, Ghassan Al-Barghouthy, Sarah Rose, Peter Jenne. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental neurology. vol 204. issue 1. 2007-05-10. PMID:17113078. |
current concepts suggest that pulsatile stimulation of dopamine receptors following l-dopa administration leads to priming for dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (mptp)-treated primates, while continuous dopaminergic stimulation with long-acting dopamine agonists does not. |
2007-05-10 |
2023-08-12 |
Not clear |
| Li-Ping Liang, Jie Huang, Ruth Fulton, Brian J Day, Manisha Pate. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 16. 2007-05-07. PMID:17442816. |
aeol11207 administered either by subcutaneous or oral routes protected against mptp-induced dopamine depletion in the striatum as well as dopaminergic neuronal loss, glutathione depletion, lipid peroxidation, and 3-nt formation in the ventral midbrain. |
2007-05-07 |
2023-08-12 |
mouse |
| Yasuhiko Izumi, Hideyuki Sawada, Noriyuki Yamamoto, Toshiaki Kume, Hiroshi Katsuki, Shun Shimohama, Akinori Akaik. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. European journal of pharmacology. vol 557. issue 2-3. 2007-05-04. PMID:17161393. |
parkinson disease is characterized by selective degeneration of mesencephalic dopaminergic neurons, and endogenous dopamine may play a pivotal role in the degenerative processes. |
2007-05-04 |
2023-08-12 |
Not clear |
| Yasuhiko Izumi, Hideyuki Sawada, Noriyuki Yamamoto, Toshiaki Kume, Hiroshi Katsuki, Shun Shimohama, Akinori Akaik. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. European journal of pharmacology. vol 557. issue 2-3. 2007-05-04. PMID:17161393. |
using primary cultured mesencephalic neurons, we found that glutamate, an excitotoxin, caused selective dopaminergic neuronal death depending on endogenous dopamine content. |
2007-05-04 |
2023-08-12 |
Not clear |
| Yasuhiko Izumi, Hideyuki Sawada, Noriyuki Yamamoto, Toshiaki Kume, Hiroshi Katsuki, Shun Shimohama, Akinori Akaik. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. European journal of pharmacology. vol 557. issue 2-3. 2007-05-04. PMID:17161393. |
pramipexole, a dopamine d2/d3 receptor agonist used clinically in the treatment of parkinson disease, did not affect glutamate-induced calcium influx but blocked dopaminergic neuronal death induced by glutamate. |
2007-05-04 |
2023-08-12 |
Not clear |
| Yasuhiko Izumi, Hideyuki Sawada, Noriyuki Yamamoto, Toshiaki Kume, Hiroshi Katsuki, Shun Shimohama, Akinori Akaik. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. European journal of pharmacology. vol 557. issue 2-3. 2007-05-04. PMID:17161393. |
these results suggest that pramipexole protects dopaminergic neurons from glutamate neurotoxicity by the reduction of intracellular dopamine content, independently of dopamine d2-like receptor activation. |
2007-05-04 |
2023-08-12 |
Not clear |
| Hideto Miw. Rodent models of tremor. Cerebellum (London, England). vol 6. issue 1. 2007-05-04. PMID:17366267. |
on the other hand, dopaminergic neurotoxins, which are used in models of parkinsonism, have yet to be used for experimental analysis of tremor, because tremors induced by dopamine depletion in rodents are less remarkable than those induced by harmaline or cholinomimetics. |
2007-05-04 |
2023-08-12 |
mouse |
| G Gille, K Radad, H Reichmann, W-D Rausc. Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 9. 2007-05-02. PMID:16252065. |
synergistic effect of alpha-dihydroergocryptine and l-dopa or dopamine on dopaminergic neurons in primary culture. |
2007-05-02 |
2023-08-12 |
Not clear |
| G Gille, K Radad, H Reichmann, W-D Rausc. Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 9. 2007-05-02. PMID:16252065. |
here, we describe the novel finding that the combination of a dopamine (da) agonist, alpha-dihydroergocryptine (dhec), with l-dopa or da exerts a synergistic stimulatory effect on dopaminergic neurons in primary culture, while each substance alone had no or less effect. |
2007-05-02 |
2023-08-12 |
Not clear |
| R Moldzio, K Radad, J C Duvigneau, B Kranner, C Krewenka, C Piskernik, W D Rausc. Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 9. 2007-05-02. PMID:16463121. |
in vitro, protective effects of the dopamine agonist lisuride on complex i inhibition in primary dopaminergic cell culture have been reported. |
2007-05-02 |
2023-08-12 |
mouse |
| Kurt Rasmussen, Mei-Ann Hsu, Yili Yan. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 4. 2007-05-01. PMID:17063151. |
as there is a dense projection of orexin neurons from the lateral hypothalamus to a10 dopaminergic neurons, and some antipsychotics have been shown to increase the expression of c-fos in orexin-containing cells in the hypothalamus, we hypothesized that stimulation of orexin receptors plays a role in the effects of antipsychotics on the activity of a9 and a10 dopamine cells. |
2007-05-01 |
2023-08-12 |
rat |
| Salvatora Succu, Fabrizio Sanna, Tiziana Melis, Antonio Boi, Antonio Argiolas, Maria Rosaria Meli. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: Involvement of central oxytocin. Neuropharmacology. vol 52. issue 3. 2007-05-01. PMID:17164075. |
the present results suggest that stimulation of dopamine receptors (mainly of the d2 to d4 subtype) in the paraventricular nucleus induces the release of oxytocin in brain areas that influence the activity of mesolimbic dopaminergic neurons mediating the appetitive and reinforcing effects of sexual activity. |
2007-05-01 |
2023-08-12 |
rat |
| Neal Hermanowic. Drug therapy for Parkinson's disease. Seminars in neurology. vol 27. issue 2. 2007-05-01. PMID:17390254. |
the fundamental concepts of the medical treatment of parkinson's disease are simple, and remain based on the enhancement of dopaminergic transmission by means of levodopa and dopamine agonists. |
2007-05-01 |
2023-08-12 |
Not clear |
| Hui-Fang Cui, Jian-Shan Ye, Yu Chen, Ser-Choong Chong, Fwu-Shan She. Microelectrode array biochip: tool for in vitro drug screening based on the detection of a drug effect on dopamine release from PC12 cells. Analytical chemistry. vol 78. issue 18. 2007-04-26. PMID:16970308. |
novel, yet simple detection techniques of drug effect, including the effect of a vesicular monoamine transporter inhibitor (reserpine), a dopamine precursor (l-dopa), and a dopamine transporter inhibitor (nomifensine), on dopamine release from dopaminergic pc12 cells were developed based on a microelectrode array (mea) biochip. |
2007-04-26 |
2023-08-12 |
Not clear |